Hyperbolic tapering is not a style preference. It is the dose-reduction strategy that reflects how benzodiazepine receptor occupancy actually changes as the dose decreases. The relationship between benzodiazepine dose and GABA-A receptor occupancy follows a hyperbolic curve, not a linear one: a reduction from 4 mg to 3 mg of diazepam produces a small change in receptor occupancy, while a reduction from 1 mg to 0.5 mg produces a very large one. A taper designed in equal-mg steps therefore produces accelerating withdrawal exposure as the dose falls, which is precisely backwards from what the patient needs.
Mark Horowitz and David Taylor formalized the receptor-occupancy argument for antidepressants in a 2019 Lancet Psychiatry paper and extended it to benzodiazepines and other psychotropics in subsequent work, most comprehensively in the 2024 Maudsley Deprescribing Guidelines. The Ashton Manual had recognized the same clinical pattern decades earlier in empirical form: reductions that work well at higher doses stop working at lower doses unless the step size gets smaller. Hyperbolic tapering is the physiological explanation for Ashton’s clinical observation.
For a patient trying to find a clinician who can execute a proper hyperbolic taper, the challenge is identifying who has actually internalized this framework, as opposed to who uses the vocabulary without the underlying practice.
What Hyperbolic Tapering Actually Is
In practice, a hyperbolic taper means two things.
First, reductions are a percentage of the current dose, not a percentage of the starting dose. A 10% taper is 10% of whatever the patient is currently taking. So 4 mg becomes 3.6 mg, then 3.24 mg, then roughly 2.92 mg, and so on. The absolute mg reductions get smaller over time — not because the patient is weakening, but because the receptor-occupancy effect of each mg gets larger at low doses.
Second, the final portion of the taper requires dose precision that commercial tablets cannot provide. Below roughly 0.5 mg diazepam equivalent, the reductions become small enough that liquid or compounded formulations are needed. The Maudsley Deprescribing Guidelines provide worked schedules showing the step sizes at each dose level; the table looks like a curve because the curve is what the physiology dictates.
Third — a feature that clinicians using the vocabulary without the practice often miss — the pace is tolerance-driven, not calendar-driven. A patient who needs six weeks to stabilize between reductions gets six weeks, not four. A patient who hits a severe flare after a reduction gets a dose hold until the flare resolves, not a forced continuation on schedule.
What to Ask a Clinician
Several questions distinguish a hyperbolic practice from one that uses the word without the method.
“How do you calculate reduction step sizes as the dose gets lower?” A clinician who answers with reference to percent of current dose and explicitly mentions that step sizes get smaller is working from the framework. A clinician who describes a fixed mg step at regular intervals is not.
“Do you use liquid or compounded formulations for the final phase of the taper?” Hyperbolic tapering below 0.5 mg diazepam equivalent requires doses that tablet formulations cannot achieve. A clinician who does not work with compounded preparations cannot execute the end of a hyperbolic taper.
“What happens if I have a bad reaction to a reduction?” The right answer includes “we hold the dose,” “we may go back up slightly if needed,” and “we do not push through.” A clinician whose answer is a plan to continue reducing regardless is running a linear taper regardless of what they call it.
“Are you familiar with Horowitz and Taylor’s work?” A clinician who recognizes the reference is working from the current literature. A clinician who does not may still be a competent taper prescriber, but the conversation will require more orientation.
Red Flags
A few patterns signal that a clinician is not actually running a hyperbolic taper, whatever the terminology.
Fixed mg reductions at fixed intervals. “Drop by 0.25 mg every two weeks” is a linear taper. At higher doses it is fine; at lower doses it produces exponentially larger percentage reductions and corresponding exacerbations.
Refusal to use liquid formulations. Below a certain dose, tablet cutting cannot produce the necessary precision. A clinician who will not prescribe a compounded liquid at that point cannot complete the taper.
Time-limited expectations. “Off in six months” is a statement about the clinician’s schedule, not about the patient’s physiology. A proper hyperbolic taper for a long-term user often takes a year or more, sometimes several, and the clinician should be willing to name that timeline.
Pushing through flares. A clinician who interprets symptom exacerbations during a taper as anxiety, non-adherence, or reasons to refer to psychiatry rather than as signals to slow down is running the wrong model.
Inflexible written schedule. A taper schedule handed to the patient in writing with no adjustment mechanism treats the taper as a prescription rather than a collaborative process.
Where to Look
The practical networks overlap with what is useful for finding any clinician literate in protracted withdrawal, but with a specific hyperbolic-tapering filter.
The Benzodiazepine Information Coalition and the Alliance for Benzodiazepine Best Practices produce clinical resources that clinicians committed to hyperbolic tapering are likely to have engaged with. Referencing either organization in a first-visit call will quickly sort clinicians by familiarity.
Patient communities — BenzoBuddies and regional patient networks — are the most consistent source of referrals to clinicians who actually run hyperbolic tapers. These networks accumulate working knowledge of who can and cannot execute the method faster than any formal directory updates.
Specialty matters less than individual practice focus. Addiction medicine, psychiatry, family medicine, and integrative medicine all include clinicians competent at hyperbolic tapering. Each also includes clinicians who are not. The filter is the clinician’s work with this population, not their board certification.
Telemedicine has expanded the available pool considerably. A patient in an underserved area may have access to a hyperbolic-literate clinician in another state via telemedicine, subject to the state-specific regulations on controlled-substance prescribing via telemedicine that have shifted several times in recent years.
When No Specialist Is Available
Some patients genuinely cannot find a hyperbolic-literate clinician in their geographic or insurance reach. Two partial alternatives exist.
A willing primary care physician or psychiatrist can be educated into the framework with appropriate references. Bringing the relevant section of the Maudsley Deprescribing Guidelines or Horowitz and Taylor’s 2019 paper to a visit is often enough to orient a clinician who is receptive to evidence. Many clinicians will accept the framework when it is presented as a published method rather than as a patient preference.
For patients who cannot find a clinician at all and who are determined to self-direct, the Maudsley Deprescribing Guidelines provide worked schedules that a motivated patient can follow with basic pharmacy cooperation for liquid formulations. This is not the preferred path; a collaborative clinician is better. It is not an impossible path either, and it is preferable to continued linear tapering under a prescriber who will not adapt.
The Underlying Point
Hyperbolic tapering is the method with the physiological rationale and the clinical experience behind it. A clinician committed to it can execute a taper that a linear protocol cannot. Finding that clinician is worth the effort it sometimes requires, because the alternative — a well-intentioned taper that becomes progressively harder as the dose falls — is the pattern that produces most of the patients who later describe their taper as having destabilized them.